ReviewBioMed research international2014
MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 74 citations in OpenAlex.
- Shikonin treatment ameliorates lipopolysaccharide-induced acute liver failure in mice via regulating miR-106/MCL1 and miR-34a/SIRT1/TP53 signaling.Archives of medical science : AMS · 2026Article
- Bioinformatics and Experimental Insights Into miR-182, hsa_circ_0070269, and circ-102,166 as Therapeutic Targets for HCV-Associated HCC.Cancer reports (Hoboken, N.J.) · 2024Article
- Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients.PloS one · 2022Article
- Non-coding RNA-associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma.Journal of cellular and molecular medicine · 2022Review
- Retracted: microRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target.BioMed research international · 2021Article
- Epigenomics in Hurthle Cell Neoplasms: Filling in the Gaps Towards Clinical Application.Frontiers in endocrinology · 2021Review
- Article
- Artificial Neural Network with Composite Architectures for Prediction of Local Control in Radiotherapy.IEEE transactions on radiation and plasma medical sciences · 2019Article
- Prognostic role of miR-760 in hepatocellular carcinoma.Oncology letters · 2018Article
- circFBLIM1 act as a ceRNA to promote hepatocellular cancer progression by sponging miR-346.Journal of experimental & clinical cancer research : CR · 2018Article
- Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas.Oncotarget · 2018Article
- Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.Molecular and cellular biochemistry · 2018Review
- Article
- MicroRNA-133a Inhibits Proliferation of Gastric Cancer Cells by Downregulating ERBB2 Expression.Oncology research · 2017Article
- Prognostic microRNAs in upper tract urothelial carcinoma: multicenter and international validation study.Oncotarget · 2017Article
- The noncoding RNA HOXD-AS1 is a critical regulator of the metastasis and apoptosis phenotype in human hepatocellular carcinoma.Molecular cancer · 2017Article
- Anti-microRNA-21/221 and microRNA-199a transfected by ultrasound microbubbles induces the apoptosis of human hepatoma HepG2 cells.Oncology letters · 2017Article
- miR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma.Oncology letters · 2017Article
- The miR-383-LDHA axis regulates cell proliferation, invasion and glycolysis in hepatocellular cancer.Iranian journal of basic medical sciences · 2017Article
- High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection.BMC cancer · 2017Article
Corrections and comments
- Retraction · 2021-02-26Euphemisms for Plagiarism · Objections by Author(s) · Plagiarism of Text ·
- Retracted
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer, with dismal outcomes and an increasing incidence worldwide. Hepatocarcinogenesis is a multistep process that progresses from chronic hepatitis through cirrhosis and/or dysplastic nodule to HCC. However, the detailed molecular pathogenesis remains unclear. MicroRNAs (miRNAs), small noncoding RNAs that regulate the translation of many genes, have emerged as key factors involved in several biological processes, including development, differentiation, and cell proliferation. Recent studies have uncovered the contribution of miRNAs to the cancer pathogenesis, as they can behave as oncogenes or tumor suppressor genes. In addition, other studies have demonstrated their potential values in the clinical management of HCC patients as some miRNAs may be used as prognostic or diagnostic markers. In this review, we summarize current knowledge about the roles of miRNAs in carcinogenesis and progression of HCC. We also discuss the potential application of miRNAs as diagnostic biomarkers and their potential roles in the intervention of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.